Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sangamo Therapeutics, Inc. SGMO -- Ignore unavailable to you. Want to Upgrade?

To: polar bear who wrote (34)	5/3/2000 6:32:00 PM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 368

Polar Bear, in case you had not seen it already, here is the Gendaq's home page: gendaq.com I'd say (Sir) Aaron Klug is about the only Zinc finger guru not associated with Sangamo. Superficially, the core technologies look pretty similar: engineering by phage display, etc. Rick's pointers to the EPO site should be useful to figure this out. The section below sounds more like Ariad's approach, as far as end result goes: ......................... Inducible Gene Switches In the next 10-20 years, many breakthroughs in medicine and agriculture will be based on the introduction of (therapeutic, prophylactic or otherwise beneficial) genes into humans, animals and plants. For reasons of safety, efficacy or public acceptance, in many cases it will be necessary to control these genes using small molecules which are administered only when gene activation is required. Gendaq is pioneering the development of iZ-Switches? - zinc finger transcription factors that function only in the presence of a given small molecule. In this way, for instance, an orally active drug could control the dosage of a therapeutic gene product in a patient, or an agrochemical may be required to activate a transgene in a GM crop. ......................... PB